SlideShare a Scribd company logo
1 of 1
High resolution telomere FISH reveals anomalies in male germ cell
tumor subtypes and precursor lesion
Mohammed Talha Shekhani1, John R. Barber4, Stephania M. Bezerra1, Christopher M. Heaphy1,3, Nilda Gonzalez Roibon1, Leonardo O. Reis1, Gunes Guner1, Corinne E.
Joshu3,4, George J. Netto1,2,3, and Alan K. Meeker1,2,3
1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; 2Department of Urology, James Buchanan Brady Urological Institute at Johns Hopkins, Baltimore, MD; 3Department of
Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; 4Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Methodolgy
 Testicular germ cell tumor (TGCT) is the most common malignancy of young men between 15-40 years of age. It is biologically
unique, because it is in cells of non-somatic lineage and is an unusually curable cancer.
 We evaluated over 70 specimens (arranged on two TGCT tissue microarrays (TMAs)) using high resolution (single-cell) telomere-
specific fluorescent in situ hybridization (FISH) to delineate telomere length patterns in different testicular germ cell tumor
subtypes, as well as in their precursor lesion, intratubular germ cell neoplasia unclassified type (IGCNU). Telomere biology has
never previously been addressed in IGCNU. Oct4 is a highly specific histological marker of IGCNU, seminoma, and embryonal
carcinoma neoplastic cells. We used co-immunofluorescence against Oct4 to improve identification of cancer cells in said
lesions.
 Telomere lengths were scored as short (=1), medium (=2) or long (=3) by comparing the intensity of the telomere signals from
neoplastic cells to benign reference cell types. Reference cells are interstitial/stromal cells (short telomeres) and normal germ
cells (medium telomeres).
Abstract
Number:
3783
Summary of Key Findings
 Compared with normal germ cells, short telomeres were observed in intratubular germ cell neoplasia (IGCNU) lesions and in majority of pure seminomas
(p=0.006 and p=0.0005, respectively). In contrast, we noted longer telomere lengths in non-seminomas—cancer subtypes that also carry a worse prognosis.
Non-seminoma and seminoma components in mixed subtype demonstrated telomeres with slight variation from pure counterparts. Among the non-seminomas,
EC has the highest proportion of cases scored as having long telomeres.
 EC is the only subtype to display telomerase-independent alternative lengthening of telomeres (ALT) phenotype (43% of pure embryonal carcinomas). Loss of
ATRX or DAXX expression is strongly associated with ALT. However, neither protein anomalies existed in sub-group of EC evaluated by IHC—suggesting that there
may be (as yet undiscovered) genetic events associated with ALT in embryonal carcinoma.
 The pattern of telomere lengths among TGCT and their precursor, IGCNU, indicate that telomeres are affected early in carcinogenesis. Moreover, telomere
anomalies may contribute to tumor initiation and progression.
 Further investigation of telomeric aberration in TGCT may delineate new pathways for intervention and prognostication in this unique malignancy.
Table 2. Telomere length distributions for TGCT subtypes and IGCNU
precursor
Embryonal
Carcinoma
Seminoma Teratoma
Yolk Sac
Tumor
Mixed
Cancer cell
telomere lengths
Long (%) 42.9 14 0 33.3 N/A
Medium (%) 14.3 27.9 100 0 N/A
Short (%) 0 58.1 0 66.7 N/A
ALT Present (%) 42.9 0 0 0 15
IGCNU Present
(%)
71.4 58.1 0 33.3 70
IGCNU telomere
length
Long (%) 0 8 0 0 0
Medium (%) 0 8 0 0 7.1
Short (%) 100 84 0 100 92.9
ALT = alternative lengthening of telomeres; and IGCNU = intratubular
germ cell neoplasia of unclassified type
Table 3. Telomere lengths in mixed germ cell tumors
Embryonal
Carcinoma
Seminoma Teratoma
Yolk Sac
Tumor
N 18 9 12 9
Long (%) 38.9 66.7 0 0
Medium (%) 38.9 11.1 25 77.8
Short (%) 5.6 22.2 75 22.2
ALT (%) 16.7 0 0 0
ALT = alternative lengthening of telomeres
Figure 1. Example image a healthy seminiferous tubule and an adjacent
IGCNU/diseased tubule. (A) DAPI/Nuclear Stain/Blue and
Cy3/Telomere-FISH/Red channels. Telomeres are punctate red dots
within nuclei. Filled/solid arrow indicates neoplastic germ cell with
short telomeres (nearly absent FISH signal) in the IGCNU tubule. Open-
headed arrow indicates healthy spermatogonial stem cell’s nucleus for
comparison. (B) 3 channel (DAPI/Nuclear Stain/Blue, Cy3/Telomere-
FISH/Red and Oct4 immunostaining/Green) merged image. *(Asterisk)
= Region displaying non-specific autofluorescence (often associated
with red blood cell fragments from nearby capillaries); IGCNU =
Intratubular Germ Cell Neoplasia of Unclassified type; FISH =
fluorescence in situ hybridization; and DAPI = 4',6-diamidino-2-
phenylindole. Original magnification is 200X, scale bar is 100
micrometers.
Figure 2. Seminoma cells compared to normal healthy germ
cells from the same patient. (A) and (B) Display DAPI/Nuclear
Stain/Blue and Cy3/Telomere-FISH/Red channels. Telomeres
are punctate red dots within nuclei. (A) Shows region
containing seminoma cells and (B) shows contents of a
healthy unaffected seminiferous tubule. Insets demonstrate
enlarged cells for unequivocal telomere length comparisons.
(C) and (D) Display 3 channel (DAPI/Nuclear Stain/Blue,
Cy3/Telomere-FISH/Red and Oct4 immunostaining /Green)
merged images of (A) and (B), respectively. *(Asterisk) =
Region displaying non-specific autofluorescence; FISH =
fluorescence in situ hybridization; and DAPI = 4',6-diamidino-
2-phenylindole. Original magnification is 400X, scale bar is 50
micrometers.
Figure 3. Comparison of an embryonal carcinoma (A, top) with another
EC displaying ALT phenotype (B, below). Both panels demonstrate 3
channel (DAPI/Nuclear Stain/Blue, Cy3/Telomere-FISH/Red and Oct4
immunostaining/Green) merged image. (A) This EC shows long
telomeres in the cancer cells compared to the adjacent stroma. Inset
delineates dramatic telomere length difference between EC and a
stromal cell. (B) This ALT positive EC shows ultra-bright telomeric DNA
foci (arrows) and intracellular telomere length heterogeneity that is
characteristic. Note short telomeres in surrounding interstitium.
*(Asterisk) = Region displaying non-specific autofluorescence; ALT =
alternative lengthening of telomeres; EC = embryonal carcinoma; FISH =
fluorescence in situ hybridization; and DAPI = 4',6-diamidino-2-
phenylindole. Original magnification is 400X, scale bar is 50
micrometers.

More Related Content

What's hot

Clinical use of telomere measurement in preventive and personalized medicine ...
Clinical use of telomere measurement in preventive and personalized medicine ...Clinical use of telomere measurement in preventive and personalized medicine ...
Clinical use of telomere measurement in preventive and personalized medicine ...Life Length
 
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tu...
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tu...Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tu...
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tu...Joshua Mangerel
 
Telomerase Inhibition as Novel Cancer Therapeutic Method
Telomerase Inhibition as Novel Cancer Therapeutic MethodTelomerase Inhibition as Novel Cancer Therapeutic Method
Telomerase Inhibition as Novel Cancer Therapeutic MethodVincensanicko
 
Nanodroplet processing platform for deep and quantitative proteome profiling ...
Nanodroplet processing platform for deep and quantitative proteome profiling ...Nanodroplet processing platform for deep and quantitative proteome profiling ...
Nanodroplet processing platform for deep and quantitative proteome profiling ...Gul Muneer
 
Exploring chemo-resistance in NSCLC - Dr Martin Barr
Exploring chemo-resistance in NSCLC - Dr Martin BarrExploring chemo-resistance in NSCLC - Dr Martin Barr
Exploring chemo-resistance in NSCLC - Dr Martin BarrHannahMcCarthy31
 
SCT60103 - Chemotherapy
SCT60103 - Chemotherapy SCT60103 - Chemotherapy
SCT60103 - Chemotherapy KaiXuan Lim
 
Role of tp53 mutations in therapy related acute myeloid leukaemia(t-aml)
Role of tp53 mutations in   therapy related  acute myeloid leukaemia(t-aml)Role of tp53 mutations in   therapy related  acute myeloid leukaemia(t-aml)
Role of tp53 mutations in therapy related acute myeloid leukaemia(t-aml)Mohsin Maqbool
 
Telomere length a 21st century biomarker
Telomere length  a 21st century biomarkerTelomere length  a 21st century biomarker
Telomere length a 21st century biomarkerChris O'Reilly
 
Epidemiology and trends of asbestos-related diseases at Helsinki Asbestos 2014
Epidemiology and trends of asbestos-related diseases at Helsinki Asbestos 2014Epidemiology and trends of asbestos-related diseases at Helsinki Asbestos 2014
Epidemiology and trends of asbestos-related diseases at Helsinki Asbestos 2014Työterveyslaitos
 
Telomere maintenance as a target for drug discovery
Telomere maintenance as a target for drug discoveryTelomere maintenance as a target for drug discovery
Telomere maintenance as a target for drug discoveryDavid Wallace
 
Asbestos-related diseases - mechanisms and causation at Helsinki Asbestos 2014
Asbestos-related diseases - mechanisms and causation at Helsinki Asbestos 2014Asbestos-related diseases - mechanisms and causation at Helsinki Asbestos 2014
Asbestos-related diseases - mechanisms and causation at Helsinki Asbestos 2014Työterveyslaitos
 
Differential connectivity in neoplastic coexpression networks (BITS2014, Rome)
Differential connectivity in neoplastic coexpression networks (BITS2014, Rome)Differential connectivity in neoplastic coexpression networks (BITS2014, Rome)
Differential connectivity in neoplastic coexpression networks (BITS2014, Rome)Roberto Anglani
 
Understanding cancer -- patient-genetic_background
Understanding cancer  -- patient-genetic_backgroundUnderstanding cancer  -- patient-genetic_background
Understanding cancer -- patient-genetic_backgroundBoadicea123
 
The clinical value of telomere testing – dr. Mark Tager A4M May 2016
The clinical value of telomere testing – dr. Mark Tager A4M May 2016The clinical value of telomere testing – dr. Mark Tager A4M May 2016
The clinical value of telomere testing – dr. Mark Tager A4M May 2016Life Length
 
Telomeric G-Quadruplexes as Therapeutic Targets in Cancer
Telomeric G-Quadruplexes as Therapeutic Targets in CancerTelomeric G-Quadruplexes as Therapeutic Targets in Cancer
Telomeric G-Quadruplexes as Therapeutic Targets in CancerHIRA Zaidi
 
Telomere and q pcr 2013
Telomere and q pcr 2013Telomere and q pcr 2013
Telomere and q pcr 2013Elsa von Licy
 
Direct Sanger CE Sequencing of Individual Ampliseq Cancer Panel Targets from ...
Direct Sanger CE Sequencing of Individual Ampliseq Cancer Panel Targets from ...Direct Sanger CE Sequencing of Individual Ampliseq Cancer Panel Targets from ...
Direct Sanger CE Sequencing of Individual Ampliseq Cancer Panel Targets from ...Thermo Fisher Scientific
 
Analytical performance of a novel next generation sequencing assay for Myeloi...
Analytical performance of a novel next generation sequencing assay for Myeloi...Analytical performance of a novel next generation sequencing assay for Myeloi...
Analytical performance of a novel next generation sequencing assay for Myeloi...Thermo Fisher Scientific
 
Genomic oncology and personalized medicine
Genomic oncology and personalized medicine Genomic oncology and personalized medicine
Genomic oncology and personalized medicine C. Jeff Chang, MD, PhD
 

What's hot (20)

Clinical use of telomere measurement in preventive and personalized medicine ...
Clinical use of telomere measurement in preventive and personalized medicine ...Clinical use of telomere measurement in preventive and personalized medicine ...
Clinical use of telomere measurement in preventive and personalized medicine ...
 
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tu...
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tu...Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tu...
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tu...
 
Telomerase Inhibition as Novel Cancer Therapeutic Method
Telomerase Inhibition as Novel Cancer Therapeutic MethodTelomerase Inhibition as Novel Cancer Therapeutic Method
Telomerase Inhibition as Novel Cancer Therapeutic Method
 
Nanodroplet processing platform for deep and quantitative proteome profiling ...
Nanodroplet processing platform for deep and quantitative proteome profiling ...Nanodroplet processing platform for deep and quantitative proteome profiling ...
Nanodroplet processing platform for deep and quantitative proteome profiling ...
 
Exploring chemo-resistance in NSCLC - Dr Martin Barr
Exploring chemo-resistance in NSCLC - Dr Martin BarrExploring chemo-resistance in NSCLC - Dr Martin Barr
Exploring chemo-resistance in NSCLC - Dr Martin Barr
 
SCT60103 - Chemotherapy
SCT60103 - Chemotherapy SCT60103 - Chemotherapy
SCT60103 - Chemotherapy
 
Role of tp53 mutations in therapy related acute myeloid leukaemia(t-aml)
Role of tp53 mutations in   therapy related  acute myeloid leukaemia(t-aml)Role of tp53 mutations in   therapy related  acute myeloid leukaemia(t-aml)
Role of tp53 mutations in therapy related acute myeloid leukaemia(t-aml)
 
Telomere length a 21st century biomarker
Telomere length  a 21st century biomarkerTelomere length  a 21st century biomarker
Telomere length a 21st century biomarker
 
Epidemiology and trends of asbestos-related diseases at Helsinki Asbestos 2014
Epidemiology and trends of asbestos-related diseases at Helsinki Asbestos 2014Epidemiology and trends of asbestos-related diseases at Helsinki Asbestos 2014
Epidemiology and trends of asbestos-related diseases at Helsinki Asbestos 2014
 
Telomere maintenance as a target for drug discovery
Telomere maintenance as a target for drug discoveryTelomere maintenance as a target for drug discovery
Telomere maintenance as a target for drug discovery
 
Asbestos-related diseases - mechanisms and causation at Helsinki Asbestos 2014
Asbestos-related diseases - mechanisms and causation at Helsinki Asbestos 2014Asbestos-related diseases - mechanisms and causation at Helsinki Asbestos 2014
Asbestos-related diseases - mechanisms and causation at Helsinki Asbestos 2014
 
Jerry Shay, Telomere Testing
Jerry Shay, Telomere TestingJerry Shay, Telomere Testing
Jerry Shay, Telomere Testing
 
Differential connectivity in neoplastic coexpression networks (BITS2014, Rome)
Differential connectivity in neoplastic coexpression networks (BITS2014, Rome)Differential connectivity in neoplastic coexpression networks (BITS2014, Rome)
Differential connectivity in neoplastic coexpression networks (BITS2014, Rome)
 
Understanding cancer -- patient-genetic_background
Understanding cancer  -- patient-genetic_backgroundUnderstanding cancer  -- patient-genetic_background
Understanding cancer -- patient-genetic_background
 
The clinical value of telomere testing – dr. Mark Tager A4M May 2016
The clinical value of telomere testing – dr. Mark Tager A4M May 2016The clinical value of telomere testing – dr. Mark Tager A4M May 2016
The clinical value of telomere testing – dr. Mark Tager A4M May 2016
 
Telomeric G-Quadruplexes as Therapeutic Targets in Cancer
Telomeric G-Quadruplexes as Therapeutic Targets in CancerTelomeric G-Quadruplexes as Therapeutic Targets in Cancer
Telomeric G-Quadruplexes as Therapeutic Targets in Cancer
 
Telomere and q pcr 2013
Telomere and q pcr 2013Telomere and q pcr 2013
Telomere and q pcr 2013
 
Direct Sanger CE Sequencing of Individual Ampliseq Cancer Panel Targets from ...
Direct Sanger CE Sequencing of Individual Ampliseq Cancer Panel Targets from ...Direct Sanger CE Sequencing of Individual Ampliseq Cancer Panel Targets from ...
Direct Sanger CE Sequencing of Individual Ampliseq Cancer Panel Targets from ...
 
Analytical performance of a novel next generation sequencing assay for Myeloi...
Analytical performance of a novel next generation sequencing assay for Myeloi...Analytical performance of a novel next generation sequencing assay for Myeloi...
Analytical performance of a novel next generation sequencing assay for Myeloi...
 
Genomic oncology and personalized medicine
Genomic oncology and personalized medicine Genomic oncology and personalized medicine
Genomic oncology and personalized medicine
 

Similar to AACR 2015 Poster 04-16-2015 2005 hrs

Research Paper - Naushad Moti
Research Paper - Naushad MotiResearch Paper - Naushad Moti
Research Paper - Naushad MotiNaushad Moti
 
Research Paper - Naushad Moti
Research Paper - Naushad MotiResearch Paper - Naushad Moti
Research Paper - Naushad MotiNaushad Moti
 
Testicular microlithiasis in the setting
Testicular microlithiasis in the setting Testicular microlithiasis in the setting
Testicular microlithiasis in the setting Hidert Chusi Huamani
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...AnonIshanvi
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...daranisaha
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...JohnJulie1
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...NainaAnon
 
Critical_Role_of_PET_Scan_in_Unravelling.pdf
Critical_Role_of_PET_Scan_in_Unravelling.pdfCritical_Role_of_PET_Scan_in_Unravelling.pdf
Critical_Role_of_PET_Scan_in_Unravelling.pdfsemualkaira
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...semualkaira
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...semualkaira
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...EditorSara
 
Rare Solid Cancers: An Introduction - Slide 9 - G. Rosti - Rare male genital ...
Rare Solid Cancers: An Introduction - Slide 9 - G. Rosti - Rare male genital ...Rare Solid Cancers: An Introduction - Slide 9 - G. Rosti - Rare male genital ...
Rare Solid Cancers: An Introduction - Slide 9 - G. Rosti - Rare male genital ...European School of Oncology
 
SCT60103 Group 2 Presentation
SCT60103 Group 2 PresentationSCT60103 Group 2 Presentation
SCT60103 Group 2 PresentationJayden On
 
Dra. María Blasco - El origen de la enfermedad
Dra. María Blasco - El origen de la enfermedadDra. María Blasco - El origen de la enfermedad
Dra. María Blasco - El origen de la enfermedadFundación Ramón Areces
 
Assessment of immunomolecular_expression_and_prognostic_role_of_tlr7_among_pa...
Assessment of immunomolecular_expression_and_prognostic_role_of_tlr7_among_pa...Assessment of immunomolecular_expression_and_prognostic_role_of_tlr7_among_pa...
Assessment of immunomolecular_expression_and_prognostic_role_of_tlr7_among_pa...dr.Ihsan alsaimary
 

Similar to AACR 2015 Poster 04-16-2015 2005 hrs (20)

Research Paper - Naushad Moti
Research Paper - Naushad MotiResearch Paper - Naushad Moti
Research Paper - Naushad Moti
 
Research Paper - Naushad Moti
Research Paper - Naushad MotiResearch Paper - Naushad Moti
Research Paper - Naushad Moti
 
Testicular microlithiasis in the setting
Testicular microlithiasis in the setting Testicular microlithiasis in the setting
Testicular microlithiasis in the setting
 
ACC Cancer Cell May 2016
ACC Cancer Cell May 2016ACC Cancer Cell May 2016
ACC Cancer Cell May 2016
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
 
Critical_Role_of_PET_Scan_in_Unravelling.pdf
Critical_Role_of_PET_Scan_in_Unravelling.pdfCritical_Role_of_PET_Scan_in_Unravelling.pdf
Critical_Role_of_PET_Scan_in_Unravelling.pdf
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
 
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
Critical Role of PET-Scan in Unravelling the Dual Pathology- Review of Litera...
 
HNSS Poster Draft v6
HNSS Poster Draft v6HNSS Poster Draft v6
HNSS Poster Draft v6
 
Rare Solid Cancers: An Introduction - Slide 9 - G. Rosti - Rare male genital ...
Rare Solid Cancers: An Introduction - Slide 9 - G. Rosti - Rare male genital ...Rare Solid Cancers: An Introduction - Slide 9 - G. Rosti - Rare male genital ...
Rare Solid Cancers: An Introduction - Slide 9 - G. Rosti - Rare male genital ...
 
SCT60103 Group 2 Presentation
SCT60103 Group 2 PresentationSCT60103 Group 2 Presentation
SCT60103 Group 2 Presentation
 
ncomms11428
ncomms11428ncomms11428
ncomms11428
 
Dra. María Blasco - El origen de la enfermedad
Dra. María Blasco - El origen de la enfermedadDra. María Blasco - El origen de la enfermedad
Dra. María Blasco - El origen de la enfermedad
 
1543 2165%282004%29128-1279%3 apcsasc-2%2e0%2eco%3b2
1543 2165%282004%29128-1279%3 apcsasc-2%2e0%2eco%3b21543 2165%282004%29128-1279%3 apcsasc-2%2e0%2eco%3b2
1543 2165%282004%29128-1279%3 apcsasc-2%2e0%2eco%3b2
 
Assessment of immunomolecular_expression_and_prognostic_role_of_tlr7_among_pa...
Assessment of immunomolecular_expression_and_prognostic_role_of_tlr7_among_pa...Assessment of immunomolecular_expression_and_prognostic_role_of_tlr7_among_pa...
Assessment of immunomolecular_expression_and_prognostic_role_of_tlr7_among_pa...
 
The Cancer Genome Atlas Update
The Cancer Genome Atlas UpdateThe Cancer Genome Atlas Update
The Cancer Genome Atlas Update
 

More from Mohammed Talha Shekhani, MD (8)

meeker modified
meeker modifiedmeeker modified
meeker modified
 
College Transcript
College TranscriptCollege Transcript
College Transcript
 
Prof Adarichev Ref Letter
Prof Adarichev Ref LetterProf Adarichev Ref Letter
Prof Adarichev Ref Letter
 
Prof Mukhtar Ref Letter
Prof Mukhtar Ref LetterProf Mukhtar Ref Letter
Prof Mukhtar Ref Letter
 
Dr Chris Heaphy LOR
Dr Chris Heaphy LORDr Chris Heaphy LOR
Dr Chris Heaphy LOR
 
Talha's HS Diploma
Talha's HS DiplomaTalha's HS Diploma
Talha's HS Diploma
 
Talha's BS Diploma
Talha's BS DiplomaTalha's BS Diploma
Talha's BS Diploma
 
diploma
diplomadiploma
diploma
 

AACR 2015 Poster 04-16-2015 2005 hrs

  • 1. High resolution telomere FISH reveals anomalies in male germ cell tumor subtypes and precursor lesion Mohammed Talha Shekhani1, John R. Barber4, Stephania M. Bezerra1, Christopher M. Heaphy1,3, Nilda Gonzalez Roibon1, Leonardo O. Reis1, Gunes Guner1, Corinne E. Joshu3,4, George J. Netto1,2,3, and Alan K. Meeker1,2,3 1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; 2Department of Urology, James Buchanan Brady Urological Institute at Johns Hopkins, Baltimore, MD; 3Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; 4Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD Methodolgy  Testicular germ cell tumor (TGCT) is the most common malignancy of young men between 15-40 years of age. It is biologically unique, because it is in cells of non-somatic lineage and is an unusually curable cancer.  We evaluated over 70 specimens (arranged on two TGCT tissue microarrays (TMAs)) using high resolution (single-cell) telomere- specific fluorescent in situ hybridization (FISH) to delineate telomere length patterns in different testicular germ cell tumor subtypes, as well as in their precursor lesion, intratubular germ cell neoplasia unclassified type (IGCNU). Telomere biology has never previously been addressed in IGCNU. Oct4 is a highly specific histological marker of IGCNU, seminoma, and embryonal carcinoma neoplastic cells. We used co-immunofluorescence against Oct4 to improve identification of cancer cells in said lesions.  Telomere lengths were scored as short (=1), medium (=2) or long (=3) by comparing the intensity of the telomere signals from neoplastic cells to benign reference cell types. Reference cells are interstitial/stromal cells (short telomeres) and normal germ cells (medium telomeres). Abstract Number: 3783 Summary of Key Findings  Compared with normal germ cells, short telomeres were observed in intratubular germ cell neoplasia (IGCNU) lesions and in majority of pure seminomas (p=0.006 and p=0.0005, respectively). In contrast, we noted longer telomere lengths in non-seminomas—cancer subtypes that also carry a worse prognosis. Non-seminoma and seminoma components in mixed subtype demonstrated telomeres with slight variation from pure counterparts. Among the non-seminomas, EC has the highest proportion of cases scored as having long telomeres.  EC is the only subtype to display telomerase-independent alternative lengthening of telomeres (ALT) phenotype (43% of pure embryonal carcinomas). Loss of ATRX or DAXX expression is strongly associated with ALT. However, neither protein anomalies existed in sub-group of EC evaluated by IHC—suggesting that there may be (as yet undiscovered) genetic events associated with ALT in embryonal carcinoma.  The pattern of telomere lengths among TGCT and their precursor, IGCNU, indicate that telomeres are affected early in carcinogenesis. Moreover, telomere anomalies may contribute to tumor initiation and progression.  Further investigation of telomeric aberration in TGCT may delineate new pathways for intervention and prognostication in this unique malignancy. Table 2. Telomere length distributions for TGCT subtypes and IGCNU precursor Embryonal Carcinoma Seminoma Teratoma Yolk Sac Tumor Mixed Cancer cell telomere lengths Long (%) 42.9 14 0 33.3 N/A Medium (%) 14.3 27.9 100 0 N/A Short (%) 0 58.1 0 66.7 N/A ALT Present (%) 42.9 0 0 0 15 IGCNU Present (%) 71.4 58.1 0 33.3 70 IGCNU telomere length Long (%) 0 8 0 0 0 Medium (%) 0 8 0 0 7.1 Short (%) 100 84 0 100 92.9 ALT = alternative lengthening of telomeres; and IGCNU = intratubular germ cell neoplasia of unclassified type Table 3. Telomere lengths in mixed germ cell tumors Embryonal Carcinoma Seminoma Teratoma Yolk Sac Tumor N 18 9 12 9 Long (%) 38.9 66.7 0 0 Medium (%) 38.9 11.1 25 77.8 Short (%) 5.6 22.2 75 22.2 ALT (%) 16.7 0 0 0 ALT = alternative lengthening of telomeres Figure 1. Example image a healthy seminiferous tubule and an adjacent IGCNU/diseased tubule. (A) DAPI/Nuclear Stain/Blue and Cy3/Telomere-FISH/Red channels. Telomeres are punctate red dots within nuclei. Filled/solid arrow indicates neoplastic germ cell with short telomeres (nearly absent FISH signal) in the IGCNU tubule. Open- headed arrow indicates healthy spermatogonial stem cell’s nucleus for comparison. (B) 3 channel (DAPI/Nuclear Stain/Blue, Cy3/Telomere- FISH/Red and Oct4 immunostaining/Green) merged image. *(Asterisk) = Region displaying non-specific autofluorescence (often associated with red blood cell fragments from nearby capillaries); IGCNU = Intratubular Germ Cell Neoplasia of Unclassified type; FISH = fluorescence in situ hybridization; and DAPI = 4',6-diamidino-2- phenylindole. Original magnification is 200X, scale bar is 100 micrometers. Figure 2. Seminoma cells compared to normal healthy germ cells from the same patient. (A) and (B) Display DAPI/Nuclear Stain/Blue and Cy3/Telomere-FISH/Red channels. Telomeres are punctate red dots within nuclei. (A) Shows region containing seminoma cells and (B) shows contents of a healthy unaffected seminiferous tubule. Insets demonstrate enlarged cells for unequivocal telomere length comparisons. (C) and (D) Display 3 channel (DAPI/Nuclear Stain/Blue, Cy3/Telomere-FISH/Red and Oct4 immunostaining /Green) merged images of (A) and (B), respectively. *(Asterisk) = Region displaying non-specific autofluorescence; FISH = fluorescence in situ hybridization; and DAPI = 4',6-diamidino- 2-phenylindole. Original magnification is 400X, scale bar is 50 micrometers. Figure 3. Comparison of an embryonal carcinoma (A, top) with another EC displaying ALT phenotype (B, below). Both panels demonstrate 3 channel (DAPI/Nuclear Stain/Blue, Cy3/Telomere-FISH/Red and Oct4 immunostaining/Green) merged image. (A) This EC shows long telomeres in the cancer cells compared to the adjacent stroma. Inset delineates dramatic telomere length difference between EC and a stromal cell. (B) This ALT positive EC shows ultra-bright telomeric DNA foci (arrows) and intracellular telomere length heterogeneity that is characteristic. Note short telomeres in surrounding interstitium. *(Asterisk) = Region displaying non-specific autofluorescence; ALT = alternative lengthening of telomeres; EC = embryonal carcinoma; FISH = fluorescence in situ hybridization; and DAPI = 4',6-diamidino-2- phenylindole. Original magnification is 400X, scale bar is 50 micrometers.